Trial · NCT01466972
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
NCT01466972, Phase 2, Completed, Hope Rugo, MD; results first posted 2020-06-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib. Trials, record NCT01466972. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01466972
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
- NCT number
- NCT01466972
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- Hope Rugo, MD
- Conditions
- Breast Cancer, Breast Neoplasm
- Interventions
- Pazopanib
- First posted
- 2011-11-08
- Last updated
- 2020-07-08
- Results first posted
- 2020-06-16
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Clinical Benefit (CB) | 12 weeks | For the purpose of this study, participants who obtained a complete response (CR), partial response (PR), or stable disease (SD) at 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 were defined as having a clinical benefit from the treatment. An overall response rate of 20% was considered to be clinically meaningful. All participants who take at least two weeks of study drug and the non-steroidal aromatase inhibitor were evaluated for toxicity and efficacy |
| Secondary | Progression Free Survival | up to 2 years | Evaluate progression free survival with ongoing evaluations at 12 week intervals until progression or up to 2 years, whichever is first. |
| Secondary | Number of Participants Experiencing Any Treatment-related Adverse Events (AE) | up to 2 years | All patients who take at least two weeks of study drug and the non-steroidal aromatase inhibitor will be evaluable for treatment-related toxicity by ongoing evaluations at 4 week intervals until progression or up to 2 years, whichever is first. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Clinical Benefit (CB) | 12 weeks | Twenty-eight patients met the 2 weeks of treatment minimum needed to be considered evaluable for this endpoint. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Progression Free Survival | up to 2 years | Twenty-eight patients met the 2 weeks of treatment minimum needed to be considered evaluable for this endpoint. | weeks | MEDIAN |
| SECONDARY | Number of Participants Experiencing Any Treatment-related Adverse Events (AE) | up to 2 years | Twenty-eight patients met the 2 weeks of treatment minimum needed to be considered evaluable for this endpoint. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinical Benefit (CB) | Pazopanib in Combination With a NSAI | 13 | Participants | ||
| Progression Free Survival | Pazopanib in Combination With a NSAI | 20 | Full Range 2 to 104 | weeks | |
| Number of Participants Experiencing Any Treatment-related Adverse Events (AE) | Pazopanib in Combination With a NSAI | 26 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pazopanib in Combination With a NSAI | 30 | |
| Overall Study | COMPLETED | Pazopanib in Combination With a NSAI | 30 | |
| Overall Study | NOT COMPLETED | Pazopanib in Combination With a NSAI | 0 |
Source ClinicalTrials.gov
Adverse events56
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 15 | 30 | 21 |
| other | Diarrhea | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 11 | 30 | 13 |
| other | Abdominal pain | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 7 | 30 | 11 |
| other | Vomiting | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 5 | 30 | 10 |
| other | Constipation | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 4 | 30 | 7 |
| other | Dry Mouth | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 2 | 30 | 2 |
| other | Dyspepsia | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 2 | 30 | 2 |
| other | Gastroesophageal reflux disease | Gastrointestinal disorders | Pazopanib in Combination With a NSAI | 2 | 30 | 3 |
| other | Fatigue | General disorders | Pazopanib in Combination With a NSAI | 16 | 30 | 21 |
| other | Chills | General disorders | Pazopanib in Combination With a NSAI | 3 | 30 | 4 |
1 to 10 of 56Source ClinicalTrials.gov
See all 56 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pazopanib in Combination With a NSAI | 2 | 30 |
| Total, other adverse events | Pazopanib in Combination With a NSAI | 27 | 30 |
| Total, serious adverse events | Pazopanib in Combination With a NSAI | 8 | 30 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01466972
GET https://conductscience.org/api/trials/v1/NCT01466972/events?page=2